Endometrial carcinoma, Neoplasia, Prognostic markers


Endometrial carcinoma represents the most common gynaecologic malignancy, which frequently arises from malignant progression of endometrial intraepithelial neoplasia (EIN). Nowadays, there are no defined prognostic markers for the prognosis of the malignant progression of EIN and it still represents the subject of various investigations. Different studies indicate, that sex hormone receptors, DNA damage and apoptosis proteins, as well as epithelial-mesenchymal transformation markers play an important role in the progression of EIN. However, most of the published studies are full of contradictory results, which indicates that additional studies are necessary. In current review, we will discuss the current knowledge about the mentioned markers in terms of the prognosis of EIN.


Download data is not yet available.


R. L. Siegel and K. D. Miller, “Cancer Statistics , 2020,” vol. 70, no. 1, pp. 7–30, 2020.

A. Raffone et al., “Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis.,” Arch. Gynecol. Obstet., vol. 299, no. 5, pp. 1233–1242, May 2019.

M. H. Vetter et al., “Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia.,” Am. J. Obstet. Gynecol., vol. 222, no. 1, pp. 60.e1-60.e7, Jan. 2020.

S. E. Kane and J. L. Hecht, “Endometrial intraepithelial neoplasia terminology in practice: 4-year experience at a single institution.,” Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol., vol. 31, no. 2, pp. 160–165, Mar. 2012.

M. A. Clarke et al., “Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms.,” Am. J. Obstet. Gynecol., vol. 223, no. 4, pp. 549.e1-549.e13, Oct. 2020.

K. Sobczuk and A. Sobczuk, “New classification system of endometrial hyperplasia WHO 2014 and its clinical implications,” Prz. Menopauzalny, vol. 16, no. 3, pp. 107–111, 2017.

K. Sobczuk and A. Sobczuk, “New classification system of endometrial hyperplasia WHO 2014 and its clinical implications,” Prz. menopauzalny = Menopause Rev., vol. 16, no. 3, pp. 107–111, Sep. 2017.

A. Travaglino et al., “Endometrial hyperplasia and the risk of coexistent cancer : WHO versus EIN criteria,” pp. 676–687, 2019.

M. Karlikova, O. Topolcan, O. T. J. Wolfe, V. Barak, and T. Zima, “Optimal Use of Biomarkers in Oncology.,” BioMed research international, vol. 2015. p. 423159, 2015.

N. Fuentes and P. Silveyra, “Estrogen receptor signaling mechanisms.,” Adv. Protein Chem. Struct. Biol., vol. 116, pp. 135–170, 2019.

S. L. Young, “Oestrogen and progesterone action on endometrium : a translational approach to understanding endometrial receptivity,” Reprod. Biomed. Online, vol. 27, no. 5, pp. 497–505, 2013.

A. C. Rodriguez, Z. Blanchard, K. A. Maurer, and J. Gertz, “Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions,” Horm.Cancer, vol. 10, no. 2, pp. 51–63, 2019.

K. Hu, G. Zhong, and F. He, “Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma.,” Int. J. Gynecol. cancer Off. J. Int. Gynecol. Cancer Soc., vol. 15, no. 3, pp. 537–541, 2005.

Swasti, “Estrogen and Progesterone Receptors in Endometrial Cancer : Where Are We Today ?,” Gynecol. Obstet., vol. 8, no. 2, pp. 9–10, 2018.

S. L. Grimm, S. M. Hartig, and D. P. Edwards, “Progesterone Receptor Signaling Mechanisms.,” J. Mol. Biol., vol. 428, no. 19, pp. 3831–3849, Sep. 2016.

M. Shah, S. R. Jain, G. Oprea, and S. Shafi, “Prognostic significance of hormone receptor (ER/PR) status in endometrial carcinoma in black women: Implications with lymph node metastasis.,” J. Clin. Oncol., vol. 38, no. 15_suppl, pp. e18099–e18099, May 2020.

V. Chandra, J. J. Kim, D. M. Benbrook, A. Dwivedi, and R. Rai, “Therapeutic options for management of endometrial hyperplasia,” J. Gynecol. Oncol., vol. 27, no. 1, pp. e8–e8, Jan. 2016.

R. Mizuno, K. Kawada, and Y. Sakai, “Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer.,” Int. J. Mol. Sci., vol. 20, no. 24, Dec. 2019.

C. C. Faloppa et al., “NF-κB and COX-2 expression in nonmalignant endometrial lesions and cancer.,” Am. J. Clin. Pathol., vol. 141, no. 2, pp. 196–203, Feb. 2014.

P. A. Sanderson, H. O. D. Critchley, A. R. W. Williams, M. J. Arends, and P. T. K. Saunders, “New concepts for an old problem: the diagnosis of endometrial hyperplasia.,” Hum. Reprod. Update, vol. 23, no. 2, pp. 232–254, Mar. 2017.

C.-Y. Chen, J. Chen, L. He, and B. L. Stiles, “PTEN: Tumor Suppressor and Metabolic Regulator.,” Front. Endocrinol. (Lausanne)., vol. 9, p. 338, 2018.

A. Raffone et al., “Loss of PTEN expression as diagnostic marker of endometrial precancer : A systematic review and meta ‐ analysis,” no. July 2018, pp. 275–286, 2019.

G. L. Mutter, M. C. Lin, J. T. Fitzgerald, J. B. Kum, and C. Eng, “Changes in endometrial PTEN expression throughout the human menstrual cycle.,” J. Clin. Endocrinol. Metab., vol. 85, no. 6, pp. 2334–2338, Jun. 2000.

Y. Xiong, Y. Y. Xiong, and Y. F. Zhou, “Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma.,” Eur. J. Gynaecol. Oncol., vol. 31, no. 2, pp. 160–164, 2010.

T. Cirpan, M. C. Terek, L. Mgoyi, O. Zekioglu, O. Iscan, and A. Ozsaran, “Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium.,” Eur. J. Gynaecol. Oncol., vol. 27, no. 4, pp. 389–392, 2006.

A. Travaglino et al., “PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer?,” APMIS, vol. 127, no. 4, pp. 161–169, Apr. 2019.

F. Mantovani, L. Collavin, and G. Del Sal, “Mutant p53 as a guardian of the cancer cell,” Cell Death Differ., vol. 26, no. 2, pp. 199–212, 2019.

A. Yemelyanova et al., “Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: An immunohistochemical and nucleotide sequencing analysis,” Mod. Pathol., 2011.

L. A. van Werkhoven, J. A. van der Zande, M. Z. Dorman, K. Schelfout, P. C. Ewing-Graham, and H. C. van Doorn, “P53 Endometrial intraepithelial neoplasia (EIN) in minimally invasive endometrial biopsies, preliminary results of a prospective observational study,” Int. J. Gynecol. Cancer, vol. 29, no. Suppl 4, p. A87 LP-A89, Nov. 2019.

Y. Jung and J. Park, “Wnt signaling in cancer : therapeutic targeting of Wnt signaling beyond β -catenin and the destruction complex,” Exp. Mol. Med., pp. 183–191, 2020.

A. Travaglino et al., “Immunohistochemical Nuclear Expression of β-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer,” Am. J. Clin. Pathol., vol. 151, no. 5, pp. 529–538, Apr. 2019.

T.-Y. Na, L. Schecterson, A. M. Mendonsa, and B. M. Gumbiner, “The functional activity of E-cadherin controls tumor cell metastasis at multiple steps.,” Proc. Natl. Acad. Sci. U. S. A., vol. 117, no. 11, pp. 5931–5937, Mar. 2020.

I. González-Rodilla et al., “The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.,” Anticancer Res., vol. 33, no. 11, pp. 5091–5095, Nov. 2013.

J. Kale, E. J. Osterlund, and D. W. Andrews, “BCL-2 family proteins : changing partners in the dance towards death,” Nat. Publ. Gr., vol. 25, no. 1, pp. 65–80, 2017.

S. O. Hong et al., “BCL-2 and BAX Expression in Normal Human Endometrium.,” Clin Exp Reprod Med, vol. 27, no. 3, pp. 245–251, Sep. 2000.

M. Laban, E. A.-S. Ibrahim, W. Agur, and A. M. B. Elddin Ahmed, “Bcl-2 may play a role in the progression of endometrial hyperplasia and early carcinogenesis, but not linked to further tumorigenesis(☆).,” J. Microsc. Ultrastruct., vol. 3, no. 1, pp. 19–24, 2015.




How to Cite